{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:22:10Z","timestamp":1774045330767,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"30","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"publisher","award":["TCRD\u2010TPE\u2010112\u201050"],"award-info":[{"award-number":["TCRD\u2010TPE\u2010112\u201050"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"publisher","award":["TCRD\u2010TPE\u2010112\u201049"],"award-info":[{"award-number":["TCRD\u2010TPE\u2010112\u201049"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cyclin\u2010dependent kinases 4 and 6 inhibitors (CDK4\/6i) have been shown to improve progression\u2010free survival (PFS) in patients with metastatic breast cancer (MBC) in randomized control trials. This study aimed to evaluate the efficacy and safety of CDK4\/6i in patients with advanced breast cancer (ABC) in a clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive patients with ABC were treated between October 2019 and March 2023 at Taipei Tzu Chi Hospital, Taiwan. Patients who had received at least one dose of CDK4\/6i were included in this retrospective study. The main outcome of this study was efficacy based on the treating physicians' assessments in terms of PFS, and overall survival (OS), as well as the factors associated with patient outcome. The secondary outcome was safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 85 patients were included in the analysis, with a mean age of 66.8\u2009years. After a median follow\u2010up of 16.1\u2009months, the median PFS was 28.4\u2009months (95% CI: 22.5\u201333.6) and the median OS could not yet be estimated. The most common adverse events (AE) were fatigue (50.8%), anorexia (45.9%), and leukopenia (44.7%). In multivariable analysis, treatment with CDK4\/6i with any grade AE or response to treatment effect (CR\/PR) was an independent predictor for longer PFS (hazard ratio [HR]\u2009=\u20090.27, 95% CI: 0.11\u20130.68; HR\u2009=\u20090.21, 95% CI: 0.06\u20130.67; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CDK4\/6i administered in a real\u2010world setting exhibits a similar survival benefit with the clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15090","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T04:10:45Z","timestamp":1693887045000},"page":"3012-3019","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of cyclin\u2010dependent kinase 4\/6 inhibitor in patients with advanced breast cancer: A real\u2010world experience"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-5682","authenticated-orcid":false,"given":"Tzu\u2010Rong","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Taipei Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation  New Taipei City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia\u2010Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of General Surgery, Department of Surgery, Taipei Tzu Chi Hospital The Buddhist Medical Foundation  New Taipei City Taiwan"},{"name":"School of Medicine Buddhist Tzu Chi University  Hualien Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta\u2010Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation  New Taipei City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.008"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.04.002"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30804-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4901-0"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0121-y"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_8_15_1","unstructured":"National Cancer Institute [webpage on the Internet] Common terminology criteria for adverse events (CTCAE) version 5.0. [Accessed August 5 2022].2018Available from:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00245"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091242"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy448"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0396"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30786-7"},{"issue":"15","key":"e_1_2_8_25_1","first-page":"505","article-title":"Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial)","volume":"38","author":"Khan QJ","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1804613"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01193-z"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:22:06Z","timestamp":1698279726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":26,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/1759-7714.15090"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15090","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"2023-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}